XXSS
GENERIC MADRID TRANSACTION SENT TO IB
07/08/2026
Back to search
Official data from USPTO
CAELUS PHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
CAELUS PHARMACEUTICALS
ST13
US500000079222834Class
5, 10
Filing
79222834
Registration
5619593
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
41
Latest update
07/08/2026
Trademark type
Word
Nice classes
5, 10
Filing date
06/01/2017
Registration date
12/04/2018
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/07/2025
Last transaction
07/08/2026
Responsible office
United States Patent and Trademark Office
Status code
707
Official register
Principal Register
Drawing code
4
Owner type
26
Owner location
Zegveld, NL
Examiner
CALIENDO, COURTNEY MICHELLE
Current location
Historical data usage
Holders and representatives
Holders
Caelus Pharmaceuticals B.V.
Caelus Pharmaceuticals B.V.
Representatives
Roberto Ledesma Law Office of Roberto Ledesma
Technical classification
Nice Classes
Class 5Class 10
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical products for treating cardiometabolic disorders; dietetic foodstuffs adapted for medical use and dietetic substancesdietetic foods adapted for medical use; food supplements for human beings; medical preparations and articles for the treatment of cardiometabolic disorders; diagnostic preparations for medical use; pharmaceutical products and natural medicinesboth for the treatment of cardiometabolic disorders; vaccines; pharmaceutical preparationsmedicines and vaccinesfor the prevention of diabetes mellitusCrohn's disease and ulcerative colitis disease ; pharmaceutical preparationsmedicines for the treatment of diabetes mellitusCrohn's diseaseulcerative colitis disease and metabolic syndrome being insulin resistance; dietetic nutritional food additives for medical purposes in the nature of natural food extracts derived from gut-microbiota and dietetic preparationsdietary supplements; dietary food preparationsdietetic nutritional food additives for medical purposes in the nature of natural food extracts derived from gut-microbiota and dietetic substances in the nature of dietary supplements for the prevention of diabetes mellitusCrohn's disease and ulcerative colitis disease ; dietary food preparationsdietetic nutritional food additives for medical purposes in the nature of natural food extracts derived from gut-microbiota and dietetic substances in the nature of dietary supplements for the treatment of diabetes mellitusCrohn's diseaseulcerative colitis disease and metabolic syndrome being insulin resistance; medical preparationscultures of microorganisms for medical usebacterial preparations for medical use ; chemicals for the diagnosis of diabetes mellitusCrohn's disease and ulcerative colitis disease; vaccine preparations for human use
Class 10
Medical apparatus and instrumentsfor use in treating cardiovascular disease or diabetesfor monitoring vital signsblood sugar levelsAGE-levels in the skin and gut/skin microbiota composition; Medical diagnostictesting and monitoring equipmentmedical diagnostic equipment for detecting and monitoring blood sugar levelsAGEs and microbiome composition; testing apparatus for medical usemedical devices for testing blood glucosemicrobiome composition in gut and on the skintesting AGE-levelsfor testing the levels of butyrate in breath analysis; measuring devices for medical usemedical device for measuring glucoseinsulinbutyratepropionategut and skin microbiome; testing apparatus for medical useblood testing apparatusapparatus for analyzing feces or respiratory gasmedical measuring devices for medical usedevices for measuring microorganisms or gas; medical test kits for home monitoring of diabetes
Publications
History of USPTO decisions and trademark events.
41 publications found
XXCR
GENERIC MADRID TRANSACTION CREATED
07/08/2026
INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
07/08/2026
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
12/07/2025
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
04/07/2025
71.P
REGISTERED - PARTIAL SEC 71 ACCEPTED
04/07/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
04/07/2025
ES71
TEAS SECTION 71 RECEIVED
11/14/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/30/2023
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
12/04/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
04/05/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
03/18/2019
FIMP
FINAL DISPOSITION PROCESSED
03/18/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/04/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
12/04/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/18/2018
PUBO
PUBLISHED FOR OPPOSITION
09/18/2018
GPNX
NOTIFICATION PROCESSED BY IB
09/15/2018
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
08/29/2018
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
08/29/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/29/2018
ALIE
ASSIGNED TO LIE
08/13/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/02/2018
XAEC
EXAMINER'S AMENDMENT ENTERED
08/02/2018
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/02/2018
GNEA
EXAMINERS AMENDMENT E-MAILED
08/02/2018
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/02/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/06/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/06/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/06/2018
RFNT
REFUSAL PROCESSED BY IB
02/16/2018
NREP
NEW REPRESENTATIVE AT IB RECEIVED
02/15/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/12/2018
RFRR
REFUSAL PROCESSED BY MPU
01/12/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/23/2017
MAFR
APPLICATION FILING RECEIPT MAILED
12/23/2017
CNRT
NON-FINAL ACTION WRITTEN
12/22/2017
DOCK
ASSIGNED TO EXAMINER
12/19/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/19/2017
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
12/18/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/14/2017
Continuous trademark protection
Get notified about every new filing that threatens CAELUS PHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.